Tempus IO™: Immunotherapy platform

Overview

A comprehensive immunotherapy platform that provides actionable and cutting-edge services for life sciences partners advancing IO therapies, including antibody-drug conjugates (ADCs), TCR therapies, and immune checkpoint inhibitors (ICIs).

 

An all-in-one biomarker platform

  • Comprehensive real-world data (RWD): ~99% of whole transcriptome profiles contain at least one IO biomarker

  • Robust suite of IO biomarkers: 10+ IO biomarkers available through Tempus sequencing

  • Advanced analytical tech: Leverage AI- and ML-based analytical tools to unlock actionable insights

  • Immune Profile Score (IPS): First-of-its-kind biomarker utilizing DNA and RNA to prognosticate ICI response

Test design

Insights delivered with every sample

 

Assess key aspects of the tumor microenvironment (TME) and understand resistance mechanisms using standard and novel biomarker data. Tempus IO data is included with applicable next-generation sequencing (NGS) assay orders to ensure comprehensive insights without the need for additional sample collection.

Download the Tempus IO overview to learn more →

Tempus xT: Solid Tumor DNA Seq

  • Tumor Mutational Burden (TMB)

  • Microsatellite Instability (MSI)

  • Neoantigen Prediction

  • Human Leukocyte Antigen (HLA) Typing

  • HLA Loss of Heterozygosity (LOH)

  • Oncogenic Virus

  • Mismatch Repair (MMR) Proteins by IHC1

  • PD-L1 Protein quantification by IHC1

  • Mechanisms of Tumor Resistance to Immunotherapy2

  • Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

Tempus xE: Whole Exome

  • Tumor Mutational Burden (TMB)

  • Microsatellite Instability (MSI)

  • Neoantigen Prediction

  • Human Leukocyte Antigen (HLA) Typing

  • Oncogenic Virus

  • Mismatch Repair (MMR) Proteins by IHC1

  • PD-L1 Protein quantification by IHC1

  • Mechanisms of Tumor Resistance to Immunotherapy2

Tempus xF/xF+: Liquid Biopsies

  • Blood Tumor Mutational Burden (bTMB) (xF+ only)

  • Microsatellite Instability (MSI) high status (xF/xF+)

Advanced analytics

Go beyond sequencing with powerful analytics

 

Tempus’ analytical capabilities leverage AI and machine learning to enhance sequencing data, enabling the identification of potential biomarkers that correlate with therapy response. Our proprietary tools uncover novel cancer dependencies and drug targets, particularly in IO-resistant populations. Tempus also offers supplementary data, custom analyses, and specialized algorithms as add-ons to meet your specific research objectives.4

Discover Tempus Lens for in-depth data and insights →
Dashboard showing Kaplan-Meier survival curve with two lines, shaded areas, and data filtering UI.Dashboard showing Kaplan-Meier survival curve with two lines, shaded areas, and data filtering UI.

Understand ICI treatment response

 

Utilize Tempus’ Immune Profile Score (IPS), a first-of-its-kind multimodal algorithm that uses DNA and RNA to provide prognostic insights into potential outcomes following immune checkpoint inhibitor (ICI) treatment in metastatic solid tumors.

 

The algorithm generates a score that categorizes study participants into:

  1. IPS-High: Indicates a higher likelihood of favorable outcomes with ICI treatment.

  2. IPS-Low: Indicates a lower likelihood of favorable outcomes with ICI treatment.

Download the Immune Profile Score (IPS) Overview to learn more →
Kaplan-Meier curve indicates significantly higher overall survival probability for rPS-High patients.Kaplan-Meier curve indicates significantly higher overall survival probability for rPS-High patients.

Lab operations

Powering clinical development with data and technology

 

Tempus operates CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is typically completed within a median of 8 days after receiving samples.

Tempus_Lab-Info-Guide

Download our lab overview

Our science

Whole Genome Sequencing Uncovers Novel BCR::ABL1 Breakpoints and Variants In Leukemia: Implications for Personalized Medicine

An analysis of hematological samples used Tempus xH and xR assays to detect BCR::ABL1 fusions. This identified novel breakpoints with clinical implications, including one that suggests asciminib resistance, demonstrating the importance of WGS in personalized medicine.

A Multi-Omic Immune Profile Score (IPS) Stratifies Real-World Outcomes of Microsatellite Stable (MSS) Advanced Colorectal Cancer Patients Treated With Immune Checkpoint Inhibitors

An exploratory study evaluated the multi-omic IPS as an ICI biomarker in a real-world cohort of advanced MSS CRC patients. IPS-High patients showed clinically meaningful prolonged rwOS on ICI, suggesting IPS utility as an ICI-specific predictive biomarker.

MAIT Cell Abundance Within Solid Tumors Is Associated With Key Clinical Characteristics

Screening of multiregional patient-derived GTOs across glioma subtypes revealed marked variability in drug response between patients and across tumor regions, suggesting the need for multi-agent therapy and highlighting GTO utility for personalized treatment.

Ultrahigh Tumor Mutational Burden (TMB) Is Associated With Improved Survival Outcomes in Patients (Pts) Treated With Immune Checkpoint Inhibitors (ICIs)

An analysis of ICI-treated patients identified Ultrahigh TMB as a novel marker for ICI response. This group showed significantly higher rwORR and improved rwOS, characterized by a higher infiltration of T cells and myeloid cells, supporting its utility for predicting therapy benefit.

Longitudinal Changes in Circulating Tumor DNA in a Phase I Dose Escalation Study of Micvotabart Pelidotin, a First-in-Human ADC Targeting EDB+FN

A study assessed the ADC Micvotabart pelidotin MICVO in advanced solid tumors. Using the Tempus xF+ assay, a pharmacodynamic response was found: HNSCC patients showed significant reductions in ctDNA TF and bTMB by C3D1, supporting ctDNA utility as a liquid biomarker.

Real-World Analyses To Evaluate the Role of TIGIT as a Target in First-Line (1L) Metastatic Non-Small Cell Lung Cancer (mNSCLC)

An analysis of patients using Tempus xR and PD-L1 IHC assessed TIGIT. TIGIT expression correlated strongly with Teff genes but poorly with PD-L1 status, suggesting PD-L1 alone may limit identification of responders to anti-TIGIT therapies.

References

  1. Assessment of MMR proteins by IHC, including MLH1, MSH2, MSH6, and PMS2, as well as PD-L1 IHC, is available as an optional add-on for Tempus xT/xE orders. This service is not automatically included in every order and should be selected by the customer.
  2. Tempus provides information on multiple variants and features that have been reported to confer resistance to immunotherapy. This includes mutations and/or copy number alterations in immune-associated genes that affect antigen presentation or interferon signaling. (xT, xE only)
  3. Tempus performs RNA whole transcriptome sequencing when sufficient tissue samples are provided.
  4. The availability of supplementary data is dependent on the scope of the request.

The information on this page is intended for life sciences companies and focuses on research and development applications.

This is AI-enabled precision medicine

This is the future of healthcare.